MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Biomarkers

What’s new in mesothelioma

Pathologica 2018 March [Link] Ascoli V, Murer B, Nottegar A, Luchini C, Carella R, Calabrese F, Lunardi F, Cozzi I, Righi L Abstract Malignant pleural mesothelioma is a neoplasm characterized by a very poor prognosis and medico-legal implications. Diagnosis, prognosis and therapy are often challenging and include several issues. Cytological diagnosis is frequently the first […]

Comments Off on What’s new in mesothelioma

Prediagnostic detection of mesothelioma by circulating calretinin and mesothelin – a case-control comparison nested into a prospective cohort of asbestos-exposed workers.

Scientific Reports 2018 September 25 [Link] Johnen G1, Burek K, Raiko I, Wichert K, Pesch B, Weber DG, Lehnert M, Casjens S, Hagemeyer O, Taeger D, Brüning T; MoMar Study Group. Abstract Malignant mesothelioma (MM) is strongly associated with a previous asbestos exposure. To improve timely detection of MM in asbestos workers, better screening tools […]

Comments Off on Prediagnostic detection of mesothelioma by circulating calretinin and mesothelin – a case-control comparison nested into a prospective cohort of asbestos-exposed workers.

5-hydroxymethylcytosine but not MTAP methylation status can stratify malignant pleural mesothelioma based on the lineage of origin

Multidisciplinary Respiratory Medicine 2018 August 2 [Link] Bosio M, Salvaterra E, Datturi F, Morbini P, Zorzetto M, Inghilleri S, Tomaselli S, Mangiarotti P, Meloni F, Cerveri I, Stella GM Abstract BACKGROUND: Malignant pleural mesothelioma (MPM) is an aggressive tumor with poor prognosis, mainly associated with work or environmental exposure to asbestos. MPM’s molecular profile is […]

Comments Off on 5-hydroxymethylcytosine but not MTAP methylation status can stratify malignant pleural mesothelioma based on the lineage of origin

The hippo pathway provides novel insights into lung cancer and mesothelioma treatment.

Journal of Cancer Research and Clinical Oncology 2018 August 3 [Link] Liu XL, Zuo R, Ou WB Abstract PURPOSE: Lung cancer and mesothelioma are two types of respiratory disease that have fatal courses and poor prognoses. Although a substantial number of targeted small molecules and antibody drugs have been developed, the 5-year survival rates of […]

Comments Off on The hippo pathway provides novel insights into lung cancer and mesothelioma treatment.

IMP3 as a prognostic biomarker in patients with malignant peritoneal mesothelioma.

Human Pathology 2018 July 18 [Link] Hui S, Guo-Qi Z, Xiao-Zhong G, Chun-Rong L, Yu-Fei L, Dong-Liang Y Abstract Malignant peritoneal mesothelioma (MPeM) is an incurable cancer with poor prognosis and several biomarkers have been suggested for screening of MPeM. The aim of our study was to evaluate the prognostic significanceas of IMP3 and Fli-1 […]

Comments Off on IMP3 as a prognostic biomarker in patients with malignant peritoneal mesothelioma.

Pre-clinical Models for Malignant Mesothelioma Research: From Chemical-Induced to Patient-Derived Cancer Xenografts.

Frontiers in Genetics 2018 July 4 [Link] Nabavi N, Wei J, Lin D, Collins CC, Gout PW, Wang Y Abstract Malignant mesothelioma (MM) is a rare disease often associated with environmental exposure to asbestos and other erionite fibers. MM has a long latency period prior to manifestation and a poor prognosis. The survival post-diagnosis is […]

Comments Off on Pre-clinical Models for Malignant Mesothelioma Research: From Chemical-Induced to Patient-Derived Cancer Xenografts.

Biomarkers for Predicting Malignant Pleural Mesothelioma in a Mexican Population.

International Journal of Medical Sciences 2018 June 4 [Link] Aguilar-Madrid G, Pesch B, Calderón-Aranda ES, Burek K, Jiménez-Ramírez C, Juárez-Pérez CA, Ochoa-Vázquez MD, Torre-Bouscoulet L, Acosta-Saavedra LC, Sada-Ovalle I, García-Figueroa J, Alvarado-Cabrero I, Castillo-González P, Báez-Saldaña AR, Pérez-Padilla JR, Osnaya-Juárez J, Rivera-Rosales RM, García-Bazán EM, Bautista-Aragón YL, Lazcano-Hernandez E, Munguía-Canales DA, Argote-Greene LM, Taeger D, […]

Comments Off on Biomarkers for Predicting Malignant Pleural Mesothelioma in a Mexican Population.

Absence of calretinin protein expression in malignant mesotheliomas from asbestos-exposed NF2+/- mice and mouse mesothelioma cell lines from various mouse strains.

Biomarker Research 2018 June 6 [Link] Blum W, Henzi T, Châtel-Soulet HE, Pecze L, Rodriguez JW, Vrugt B, Schwaller B Abstract BACKGROUND: Calretinin is the most widespread positive marker for the immunohistochemical identification of malignant mesothelioma (MM) and was proposed to serve as a blood-based biomarker. Functionally, evidence has accumulated that calretinin might be implicated […]

Comments Off on Absence of calretinin protein expression in malignant mesotheliomas from asbestos-exposed NF2+/- mice and mouse mesothelioma cell lines from various mouse strains.

Soluble CD157 in pleural effusions: a complementary tool for the diagnosis of malignant mesothelioma.

Oncotarget 2018 April 27 [Link] Augeri S, Capano S, Morone S, Fissolo G, Giacomino A, Peola S, Drace Z, Rapa I, Novello S, Volante M, Righi L, Ferrero E, Ortolan E, Funaro A Abstract BACKGROUND: CD157/Bst1 glycoprotein is expressed in >85% of malignant pleural mesotheliomas and is a marker of enhanced tumor aggressiveness. RESULTS: In […]

Comments Off on Soluble CD157 in pleural effusions: a complementary tool for the diagnosis of malignant mesothelioma.

Antitumor efficacy of Kisspeptin in human malignant mesothelioma cells

Oncotarget 2018 April [Link] Ciaramella V, Della Corte CM, Di Mauro C, Tomassi S, Di Maro S, Troiani T, Martinelli E, Bianco R, Cosconati S, Pierantoni R, Meccariello R, Chianese R, Ciardiello F, Morgillo F Abstract PURPOSE: Kisspeptin signaling, via its receptors GPR54, could be an essential players in the inhibition of mesothelioma progression, invasion […]

Comments Off on Antitumor efficacy of Kisspeptin in human malignant mesothelioma cells